The Form 144 signals intent to sell, but the sale may not be executed. Monitor subsequent Form 4 filings to confirm actual sales. The officer's option exercise and sale plan could indicate a desire to diversify or raise cash, but the amount is modest relative to market cap.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $88.81entry
- T+1 · 6d ago +0.55%α −0.77% · $89.30
- T+4 · todayOpen
- T+5 · in 7h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ryan Savitz, an officer of Dianthus Therapeutics, filed a Form 144 notice of intent to sell 124,042 shares of common stock, with an approximate market value of $10.7 million based on the filing. The shares are to be acquired through the exercise of stock options over the next three months. This represents a notable insider sale relative to the company's $4.7B market cap.
Key Facts
- Filer: Ryan Savitz, an officer of Dianthus Therapeutics
- Shares to be sold: 124,042 shares of common stock
- Approximate market value: $10,671,333.26
- Shares to be acquired via exercise of stock options over the next three months
- Filing date: November 9, 2026
- Company market cap: $4.7B
Financial Impact
Sale of 124,042 shares valued at approximately $10.7 million, representing about 0.23% of market cap
Risk Factors
- Insider sale may signal reduced conviction or need for liquidity
- Sale may not occur; Form 144 is only an intent to sell
- No specific sale date or price provided beyond the filing date
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010869 |
| Document: 0001950047-26-010869-index.html | 0001950047-26-010869 |
| Document: 0001950047-26-010869.txt | 0001950047-26-010869 |
Track record
23 reports on DNTH
7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Viewing Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers